Gentlemen, thank you for standing by, and welcome to the Elevance Health Q3 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question and answer session where participants are encouraged to present a single question. If you wish to ask a question, please press star then one on your telephone keypad. You will hear a prompt that you have been queued. You may withdraw your question at any time by pressing star then two. These instructions will be repeated prior to the question and answer portion of this call. As a reminder, today's conference is being recorded. I would now like to turn the conference over to the company's management. Please go ahead. Good morning, and welcome to Elevance Health's Q3 2022 earnings call. This is Stephen Tanal, Vice President of Investor Relations, and with us this morning on the earnings call are Gail Boudreaux, our President and CEO, John Gallina, our CFO, Peter Haytaian, President of Carelon, Morgan Kendrick, President of our Commercial and Specialty Business Division, and Felicia Norwood, President of our Government Business Division. Gail will begin the call with a brief discussion of the quarter and recent progress against our strategic initiatives. John will then discuss our financial results and outlook in greater detail. After our prepared remarks, the team will be available for Q&A. During the call, we will reference certain non-GAAP measures. Reconciliations of these non-GAAP measures to the most directly comparable GAAP measures are available on our website, elevancehealth.com. We will also be making some forward-looking statements on this call. Listeners are cautioned that these statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of Elevance Health. These risks and uncertainties can cause actual results to differ materially from our current expectations. We advise listeners to carefully review the risk factors discussed in today's press release and in our quarterly filings with the SEC. I will now turn the call over to Gail. Thanks, Steve, and good morning, everyone. Today, we're pleased to share that Elevance Health delivered another strong quarter. This morning, we reported Q3 GAAP earnings per share of $6.68 and adjusted earnings per share of $7.53, ahead of expectations and reflecting strong revenue and earnings growth across our businesses. Based on our year-to-date results and confidence in our momentum, we are increasing our full year adjusted earnings guidance to greater than $28.95 per share, representing growth of approximately 15% off of the adjusted baseline we provided at the beginning of the year. Before we discuss the quarter in more detail, I want to spend a moment on the recent hurricanes that have tragically impacted the lives of people in Florida and Puerto Rico, including some of our own health plan members and associates who live and work in the impacted areas. As an organization deeply rooted in our communities, the impact of these disasters is personal. I'd like to thank our associates who are leading efforts to provide water, food, durable medical equipment, transportation, and shelter along with our clinical teams, social workers, and behavioral health specialists for their extraordinary commitment to support those in need. It's in times such as these that our culture shines through, and I am proud of our associates for the work they are doing to support their colleagues and communities. Turning to our business performance, we are pleased to report ongoing broad-based momentum across Elevance Health, a testament to our integrated and personalized whole health approach to addressing the physical, behavioral, and social needs of our members and communities. Our focused efforts and investments in these areas are resonating with employers and state partners, driving strong organic membership growth in our commercial and government health benefits businesses, as well as rapid growth for Carelon and IngenioRx. While our business trends remain strong, we are mindful of the inflationary pressure and general uncertainty in the economic environment and are focused on delivering affordability and value for customers and consumers in all of our businesses. Medical membership grew 5% quarter-over-quarter to 47.3 million members. Over the past year, we've grown to serve 2.2 million more consumers with both our commercial and government businesses, delivering robust growth that solidifies our position as the largest carrier by US-based medical membership. In the employer market, we continue to gain market share on the strength of our leading cost to care position and innovative consumer products, such as our Total Health Connections suite of advocacy solutions. Total Health Connections is an example of where we're delivering an integrated whole health experience for consumers by guiding members to the next step in care through a simple, intuitive, and personalized experience. Our clinical advocates help members navigate the healthcare system, leveraging real-time data analytics to identify health risks that enable our advocates to personally connect with members and help them proactively manage the medical, behavioral, and social issues impacting their health. Health Connections has grown more than 60% over the past two years and will support more than 5 million of our members in 2023. In addition to advocacy solutions, our integrated digital offerings are also gaining momentum. Sydney Health, the digital front door for our members' health needs, continues to rapidly expand the number of registered users, and is now hosting more than 6 million visits every month. We are also seeing strong member satisfaction with our virtual primary care offering, which is available through Sydney Health and integrated into our commercial products, and is increasingly being used to support members with chronic conditions such as hypertension and type two diabetes. Our findings reflect that 62% of the top 10 diagnoses to date have resulted in the treatment of chronic conditions, demonstrating that virtual primary care can improve access to needed care with the potential to improve health outcomes and reduce overall costs. Turning to our Medicare business, we're well-positioned to achieve another year of above-market growth in individual Medicare Advantage membership. For 2023, we expanded our Medicare Advantage offering to 145 new counties and added PPO plans in 210 counties, significantly increasing our reach into this important market as we continue to deliver differentiated value for seniors with strong core benefits and industry-leading supplemental offerings. With widespread pressure on the cost of daily living, affordability and value are more important for seniors than ever, and our health plans are positioned to meet their needs. Nearly 75% of our Medicare Advantage plans will have a $0 premium and no co-pays for primary care in 2023. Our supplemental benefits include popular over-the-counter offerings, transportation, dental and vision, as well as in-home support and healthy groceries. Seniors on our plans will also now have a simplified way to access and keep track of their benefits with a single prepaid card that is customized with spending amounts for their unique benefits and can be used at thousands of participating retailers or on an online portal. Medicare star ratings remain a key focus area across Elevance Health. Many of our affiliated Medicare Advantage plans continue to earn high quality scores, and we're particularly pleased with the performance of our HealthSun health plans in Florida, which received a five-star rating for the sixth year in a row in the recently released 2023 Medicare Advantage star ratings, which will impact the 2024 payment year. In aggregate, we did see a modest drop in the percentage of our members in four-star or higher-rated plans for the 2024 payment year, predominantly due to the end of COVID era relief. While we will decline by less than the overall industry, we remain intensely focused on our long-term goal of achieving and maintaining star ratings at the high end of all Medicare Advantage plans in our markets. Carelon continues to accelerate its impact and drive differentiated value for Elevance Health Plan members. In the Q3, we began implementing and rapidly scaling the myNEXUS post-acute care management product, which is now serving our Medicare Advantage members in 15 markets, with plans to add more markets in the coming quarters. This new product offering represents a major service line expansion that helps optimize appropriate levels of care post-inpatient discharge by working with acute and post-acute facilities to safely manage patient transitions, and thereby reduce hospital readmissions and average length of stay. Carelon is also delivering distinctive cost and quality results for our commercial business at scale. As we discussed earlier this year, Carelon's AIM Specialty Health business expanded its risk-based contract with our commercial health plans to perform focused management of select clinical conditions such as oncology, surgery, and diagnostic imaging to cover our entire 14-state footprint at the beginning of this year. AIM has been performing well year to date, benefiting our commercial members while producing stable, predictable cost of care for complex conditions for our commercial health plans and driving growth for Carelon. Our enterprise-wide focus on health equity remains central to our strategy and continues to guide our business decisions and targeted investments. We were pleased that our Simply Healthcare Plan in Florida recently achieved Health Equity Plus accreditation by the National Committee for Quality Assurance with an almost perfect score. Similarly, Anthem Blue Cross's individual exchange plan in California achieved NCQA distinction in multicultural healthcare. Awards like these show our commitment and progress to identify and address local, social, and physical drivers of health with an emphasis on members who need us most. These results would not be possible without the dedication of our more than 100,000 associates, and I would like to thank them for the important work they do and the impact they make every day. Their passion and commitment is reflected in our recent recognition as a great place to work for the third consecutive year, and also in our inclusion on the 2022 Fortune Best Places to Work For and PEOPLE Companies that Care. Our associates take pride in the work they do and the difference their contributions make to our company, our members, and the community. We see this every day, and most recently in the results of our associate engagement survey, which showed that 96% of associates understand and are inspired by our purpose to improve the health of humanity. These strong results and national recognitions reflect our commitment to leadership and represent our employees' experience defined by high levels of trust, respect, credibility, fairness, and pride, and help our efforts to recruit and retain top talent, a reflection of our culture. Our passion to improve lives and communities is unwavering, and we look forward to making a meaningful difference as Elevance Health. Now, I'd like to turn the call over to John for more on our operating results. John? Thank you, Gail, and good morning to everyone on the line. As Gail mentioned earlier, we reported Q3 adjusted earnings per share of $7.53, an increase of approximately 11% quarter-over-quarter, driven by broad-based momentum across our enterprise. We are pleased to have delivered another quarter of double-digit growth in revenue, operating income, and adjusted earnings per share, driven by the disciplined execution of our strategy and ongoing growth of health benefits and services businesses, progressing us further down our path of transforming from a health benefits company to a lifetime trusted partner in health. We ended the Q3 with 47.3 million members, growing 2.2 million or nearly 5% quarter-over-quarter, including growth of 232,000 members in the Q3. Our industry-leading organic enrollment growth, which constituted nearly 90% of our total enrollment growth quarter-over-quarter, was led by strong sales in our commercial fee-based membership, growth in Medicaid, driven in large part by the ongoing suspension of eligibility redeterminations, and growth in excess of the overall market in our individual Medicare Advantage business, primarily driven by dual-eligible members. We supplemented strong organic growth with the acquisitions of the Paramount and Integra Medicaid health plans, which together added approximately 300,000 Medicaid members earlier this year. Operating revenue in the Q3 was $39.6 billion, an increase of $4.1 billion or approximately 11% over the prior quarter with strong growth in each of our businesses. We earned higher premium revenue driven by membership growth in Medicaid, including the acquisitions of Integra and Paramount, Medicare, and commercial risk and fee-based membership growth, and premium rate increases to cover overall cost trends in all of our health benefits lines. Our services businesses, Carelon and IngenioRx, produced a very strong growth as we continue to execute against our long-term growth strategy. IngenioRx grew revenue 11% quarter-over-quarter, while the other segment, comprised primarily of Carelon, grew operating revenue 26%. Carelon and IngenioRx are delivering significant value to our commercial and government health plans and consistent with our strategy, we continue to increase the breadth and depth of services Carelon is providing. Revenue elimination consolidation, a proxy for affiliated business between our risk-based health plans and our services businesses, grew 17% quarter-over-quarter in the Q3, representing approximately 21% of our consolidated benefit expense, up from approximately 20% a year ago. The consolidated benefit expense ratio for the Q3 was 87.2%, a decrease of 50 basis points over the Q3 of 2021. During the quarter, we realigned certain quality improvement expenses incurred since the beginning of this year, which had a favorable impact on our benefit expense ratio and an offsetting unfavorable impact on our SG&A expense ratio with no impact on operating earnings. Excluding the impact of the accounting realignment, our benefit expense ratio would have been approximately flat quarter-over-quarter and better than our expectations. We were pleased to deliver operating margin expansion in our commercial business, driven in part by stronger medical underwriting performance in our commercial group risk business. The successful July 1 renewal process, where we repriced approximately 25% of our large group risk business and the continued increases in penetration of services into our fee-based businesses contributed to the segment's performance. We were pleased with the retention of our July 1 renewals and have even more confidence as we approach the January 1 renewal date. Elevance Health's SG&A expense ratio in the Q3 was 11.4%, an increase of 30 basis points over the prior year quarter. The increase was primarily driven by spend to support growth and the realignment of certain quality improvement expenses, as previously described. Excluding the realignment, our SG&A ratio would have improved by approximately 20 basis points quarter-over-quarter. Q3 operating cash flow was $4.9 billion or 3.1 times net income, driven primarily by the early receipt of certain fourth quarter premium revenue from CMS during the Q3. We also paid our share of the Blue Cross Blue Shield Association's litigation settlement of approximately $500 million in the quarter. Excluding both of these items, operating cash flow would have been $3 billion or 1.9 times net income, another indication of high quality earnings. Turning to our balance sheet, we ended the Q3 with a debt to capital ratio of 39.7% in line with our expectations and consistent with our target range. During the quarter, we repurchased approximately 1.2 million shares of common stock for $579 million. Year to date, we've been opportunistic with respect to share repurchases during periods of volatility in our share price and have already repurchased 3.7 million shares for $1.7 billion, exceeding our initial outlook of repurchasing at least $1.5 billion in 2022. We continue to maintain a prudent posture with respect to reserves. Days in claims payable stood at 47.7 days at the end of the Q3, a decrease of 0.1 days sequentially, but an increase of 0.9 days year over year. Given strong performance year to date, we are increasing our full year earnings outlook. We now expect adjusted earnings per share to be greater than $28.95, implying growth of approximately 15% off the adjusted baseline of $25.20 provided at the beginning of the year. Our businesses are continuing to perform well with strong momentum that we expect will carry into 2023. While we will not provide specific guidance for 2023 on this call, I would like to review some known tailwinds and headwinds worth considering as we continue planning for 2023. Starting with the tailwinds. The continued execution of our commercial margin recovery in 2023 through disciplined underwriting to cover our forward view of medical cost trends, enhanced operating efficiencies, and ongoing strategies to improve the productivity and profitability of our commercial fee-based business. The growth we anticipate in our individual ACA and employer-sponsored membership as consumers transition coverage when Medicaid eligibility redeterminations resume. We expect strong earnings growth in Medicare Advantage, driven by membership growth in excess of the broader market and operating margin expansion that we expect will be driven by three primary factors. Number one, having 73% of our Medicare Advantage members in four-star or higher rated plans for the 2023 payment year, an increase of 15 percentage points quarter-over-quarter. Number two, the continued recovery in risk adjustment as utilization has returned to more normalized levels. Number three, a relatively strong funding environment for the overall industry in 2023. Finally, we expect ongoing momentum in Carelon services and in IngenioRx, which will carry in the next year. Our tailwinds will be weighed against one known headwind, and that is the membership attrition and related impacts on our Medicaid business as eligibility redeterminations are conducted over the course of the next year. Although interest rates continue to rise rapidly, investment income is not expected to be a material tailwind or headwind. In 2022, we enjoyed significant outperformance in our alternative investments in the H1 of the year. Rising interest rates are expected to benefit the H2. We are anticipating a full year of benefit from higher rates in 2023. While performance in both years is expected to be strong overall, I would not call out investment income as a material tailwind or headwind for either 2023 or 2022 at this point. We're also mindful of the uncertain economic environment and the risk that business conditions could deteriorate. While the balance and resilience of our enterprise and the momentum we have across our businesses leaves us well-positioned for growth in the coming years, a more severe recession could create challenges. Our associates are prepared to adapt to any change in the business environment with detailed plans that ensure we will remain positioned to meet the unique needs of our clients and customers as they evolve, with a commitment to affordability and value throughout. Accordingly, at this point in time, we expect to produce another year of growth in adjusted earnings per share in line with our long-term target compound annual growth rate in 2023, which is consistent with the current consensus estimate. We look forward to providing more specific guidance on our fourth quarter earnings call. In closing, we continue to execute against the strategic priorities we mapped out at our 2021 investor conference and are pleased to have delivered another strong quarter while also continuing to reinvest in our business, better positioning us to deliver strong growth for years to come. With that, operator, please open the line for questions. Ladies and gentlemen, if you wish to ask a question, please press star, then one on your telephone keypad. You will hear a prompt that you have been queued. You may withdraw your question at any time by pressing star, then two. If you are using a speakerphone, please pick up the handset before pressing the numbers. Once again, we ask that each participant limit themselves to a single question to allow ample time to respond to each participant that may wish to participate in this portion of the call. For our first question, we'll go to the line of Justin Lake from Wolfe Research. Please go ahead. Hey, guys. Thanks for the question. This is Andrew Mok on for Justin Lake here. On commercial margins, just focusing on that for a second. You know, you guys showed some sequential improvement there, but looks like you probably need around 300 basis points to kind of hit that 25 target range that you laid out there. Just curious on the pacing of that. How much are you expecting to come in 2023 and 2024? Maybe a slight follow-up there. You mentioned retention, John Gallina. You know, how did that track versus typical on those July 1 renewals? Thanks. Yeah, no, thank you for the question, and maybe I'll start out and then turn it over to Morgan Kendrick to fine-tune some of the comments on retention. In terms of the pacing, you know, as I had stated, you know, 90 days ago, you know, we expect that, you know, that 300 basis points is a 2025 target, and it'll be a little bit more heavily weighted to the beginning half of the timeframe. As you know, we just repriced about 25% of our large group fully insured business here on July 1. We're gonna reprice about 50% of that business on January 1. The other 25% goes throughout the year. Obviously, it's gonna take a couple years for that to get to the point where it needs to get to. The really nice trajectory and improvement we're having on upselling our fee-based businesses, our 5-1 to 3-1 strategy. It's going very much in accordance to our expectations and the plans that we laid out, which actually do have us going through 2025. I think the short answer to your question is, a lot more of the improvements early on, but we will take till 2025 to get there. With that, Morgan. Yeah, yeah. Thanks, John, and thanks for the question, Justin. You know, as John said, this is gonna be—it's gonna take a bit to get it completely turned. July came in actually as expected. Certainly, there was some attrition in the large group risk business. To give you some context there as it relates to January, John said about 50% of that business is up for renewal. We have just released those in market, so it's a bit early to tell, but our expectations are that there will be some attrition, which would be natural when we're right pricing this business. We're you know, unmoved by anything being different than expected, as we move forward. Thanks, Morgan, and thanks, Andrew, for the question. I think as you heard from both John and Morgan, we feel we're making really good progress in this business. As I shared in my opening comments, we're seeing really strong uptake, particularly in our fee-based business, along with the discipline process. I'd say overall, it met our expectations on attrition to be real specific. Overall, feel very good about the quarter and where we're heading on commercial. Next question, please. Next, we'll go to the line of A.J. Rice from Credit Suisse. Please go ahead. Hi, everybody. Thanks for the question. Maybe just get you to comment a little bit on the trends in the government business. I know you swung to a little bit of a decline in margin year to year in the government. Can you just parse out a little bit more what you're seeing there? Any read on the landscape files and your expectations around MA growth next year? I know you said, John, I think solid growth. I'm just wondering if there's any way to flesh that out further at this early date. Thank you for the question, A.J. You know, our Government Business Division is actually performing very well. For the year, we're certainly gonna be posting some very strong results. You know, both Medicaid and Medicare have been growing nicely, and I think that's evidenced by the excellent top-line growth we've seen of over 13% quarter-over-quarter. You know, Medicaid's performance is strong, but you know, from Medicaid, and we've said this in the past, on a quarterly basis, results can be a bit more variable and susceptible to swings. When viewed in isolation, any one quarter could be misleading. You know, Medicare is continuing to perform consistent with our expectations, and as you know, has significant upside for 2023. You think about Medicare and the improving star ratings that I talked about in my prepared comments, the more complete and accurate risk scoring that will allow us to enhance the revenue in those areas. We feel very well positioned for the future of our Medicare Advantage book. You know, in terms of 2023 growth, it is premature to provide specifics associated with 2023 growth, but our goal is to clearly grow faster than the industry. We have done that on a percentage basis now for the last several years in a row and expect to do that for the next several years, ongoing. Thank you for the question, AJ. Yeah. Thanks, A.J. Maybe I'll ask Felicia Norwood, who leads our government business, to provide a little bit more color on our Medicare Advantage. You know, it's early. We just started the AEP process, and as John said, we feel confident about above-market growth. She can give you a little perspective on just how we're seeing the marketplace. Felicia? Yeah. Thank you, Gail, and good morning, A.J. As Gail said, it was certainly very early in the Medicare Advantage annual election period. You know, we're pleased with what we've seen so far around our competitive positioning. You know, when we think about our supplemental benefits, they really compare favorably with our competitors, and we really lead the industry in terms of our everyday extras, our over-the-counter offerings, transportation benefits, and certainly those things that are focused on addressing the whole health needs of our members and those social drivers of health. Additionally, as you know, we actually improved our footprint by expanding into 145 new counties on the HMO side and then 210 counties from a PPO perspective. While we're early in this process, based on the feedback we're getting from our distribution channel and others, we feel very good about how we are positioned as we head into AEP and look forward to continued growth in this business. Thank you. Thanks for the question. Next question, please. Next, we'll go to the line of Lance Wilkes from Bernstein. Please go ahead. Yeah, thanks, and good morning. Can you talk a little bit about IngenioRx? What I'm interested in is both progress in cross sales for 2023 that you're seeing thus far in the self-insured book. Then with the contract with CVS ending in 2024, just wondering if you're entering into sort of a rebidding process or what the strategy is on a go-forward basis for that. Thanks. Yeah, thanks for the question, Lance. I'm gonna have Peter Haytaian, who leads that business, give you a perspective on IngenioRx. But overall, just to say we're really pleased, seeing some really strong growth in IngenioRx and, more importantly, integrating it into our 5-1 and 3-1 strategy. I think Pete can provide you a lot more granularity on kinda what we're seeing in the market. Pete? Yeah, thanks a lot, Lance, for that question. We are very pleased with both the operating performance and the growth in IngenioRx. Just to put a little bit more color on that, you know, we are, as you know, trying to be a different PBM. We're talking about the integrated whole health value proposition, and that does continue to play through nicely in the marketplace. This year, we're seeing, as it relates to your specific question on the ASO growth from 5-1 to 3-1, about a 300% improvement quarter-over-quarter in terms of net new members that we're selling this year. We're seeing good RFP activity. I'd say really strong performance in the middle and down market, where we perform very, very well financially and where integration actually plays very well. Up market, as you would expect, there's a little bit more stickiness, especially in light of the economic situation we're in. Overall, we feel very good about our growth and prospects, as we move forward. As we head into next year, you know, we're already into the 2023 selling season. It's well underway. We have good visibility on our growth. Again, we're seeing a lot of activity in the middle market and down market. The feedback we're getting right now from the brokers from a distribution perspective is our headline rates look really good. The other thing that we're very focused on as it relates to IngenioRx is upselling additional products and services. Things like cost relief programs, specialty condition management programs, and digital adherence programs. It's moving in the right direction. Thank you. Next question, please. Next, we'll go to the line of Scott Fidel from Stephens. Please go ahead. Hi. Thanks. Good morning. Was interested if you could just talk about the competitive environment in managed Medicaid a bit, particularly as we're in a pretty active RFP cycle right now and with a couple of other big states coming up and with a couple of the competitors having, you know, shown some improved momentum in some of the recent RFP results. You know, interested just in the competitive backdrop and then what Elevance is doing right now, strategically or tactically to try to keep your competitive edge in Medicaid. Thanks. Thank you. I'm gonna ask Felicia Norwood to address your question. Good morning, Scott. You know, in many respects, the Medicaid space has always been competitive, but you're right, it's certainly become hyper-competitive recently, and we continue to be, I think, well positioned around our success. When I take a look at the RFP process, as you know, states really delayed part of the RFP process in the midst of COVID, but things have certainly wrapped up significantly over the past year or so. When I take a look at where we are, our focus has really been around health equity, population health. You heard Gail reference earlier our NCQA distinction with respect to health equity. Our state partners are certainly looking at health plans who can help them improve outcomes and focus specifically on those health equity areas that we've been working on here at Elevance Health. I feel strongly about our ability to kind of elevate and advance health for our members and address the needs of our state partners at a local level. When I look at the RFP opportunities we've been focused on, you know, certainly California was significant, a really big win for us. We won in every county we were able to win in, and we actually picked up a county that was a new county for us. A very strong performance there. We recently also reprocured our RFP in Puerto Rico, coming in first, and that demonstrated to me continued strong momentum in terms of our ability to address the needs of our state partners. Most recently yesterday, having the D.C. City Council approve a new win for us in the district. I continue to see momentum around our value proposition being able to respond to the needs of our state customers and meet our Medicaid members where they are as we continue to focus on health equity, improved outcomes, and advancing those issues that we know are very important to our state partners. Thank you. Next question, please. Next, we'll go to the line of Nathan Rich from Goldman Sachs. Please go ahead. Good morning. Thanks for the question. I wanted to ask on, medical cost trend. I think, you know, the MCR was flat quarter-over-quarter, excluding the accounting adjustment. Last quarter, John, I think you had talked about medical cost trend being elevated in the back half of the year, but it sounded like that might have come in a little bit better than your expectations. What did you see play out by line of business? As we think about your outlook for next year, how are you thinking, utilization will trend, into 2023? If I could just add a quick clarification on the accounting adjustment. Could you provide more details on what costs moved out of benefit expense? I guess importantly, you know, whether future periods will be impacted by this change. Thank you. Thank you for the questions, Nathan. Let me do the easy one first, and that was the accounting adjustment. You know, during the Q3, you know, CMS provided clarifying guidance on the types of costs that can be included in the quality improvement cost, and therefore considered benefit expense versus those that need to be classified as SG&A. You know, our GAAP presentations have historically always mirrored the CMS definitions and requirements. When CMS clarified those definitions, we realigned our reporting accordingly. Just to be clear, the impact for the Q3 was to improve MCR by about a half of one percent, which would then make the negative impact on SG&A about one half of one percent with no impact on the bottom line. Clearly a reclass. For the full year, there will be about a 20 basis point impact on each of those. We always try to be fully transparent. We wanted to ensure everyone was aware of the nuances in this reporting and what we will see by the end of the year of about a 20 basis point benefit to MLR for this clarification that CMS provided that we aligned with. Hopefully that helped from that perspective. In terms of the trends and costs and utilization in general, you know, as you stated, you pointed out, without the reclassification, our MLR would have been flat, which is actually a nice improvement because of the mix on a mix-adjusted basis, you know, since our government membership now is a higher percent of our fully insured membership than it was a year ago. Q3 did come in better than expected, but the overall cost structure of the health system is still a bit higher than what it would have been had COVID never occurred. I think the most important element of all this is that our trends continue to be in line with our expectations in each of our lines of businesses. You know, associated with lines of businesses, Medicaid is doing slightly better than historical levels. You know, Medicare is very much in line. You know, we're seeing outpatient a bit higher and inpatient a bit lower, helping offset to have a more normalized trend. Commercial has been very consistent with our last several quarters, where outpatient continues to be higher, but even more so than the benefit that we're seeing in inpatient. That's been all part of the process and all part of the guidance. We're obviously not going to comment on 2023 at this point in time, but hopefully that answers all your questions. Next question, please. Next, we'll go to the line of Stephen Baxter from Barclays. Please go ahead. Great. Thanks. Good morning, everybody. I guess just, you know, regarding the potential migration in 2023 of the ineligible Medicaid members into commercial and exchange plans, I guess I'm curious whether or not there's been any evolution in your key states that might allow Elevance to more directly funnel your own ineligible Medicaid members into your own exchange plans. Could this be more of a controlled process for the industry now versus maybe, you know, where it stood a year ago? Would you still just describe the Medicaid market environment for 2023 as really just kind of a big jump ball for all MCOs to try to grab the ineligible Medicaid members next year? Thanks. Well, Steve, thanks for your question. I think just a couple of, I'd say, clarifications. As we go through this process. We've been working very, very closely with our states and across our enterprise. A few things that I think are important, that we shared with you in the past. One, we've had a long time to plan for this and a long time to discuss this with each of our specific states. Each state will have a bit of a different process, but where we can, we're sharing data that the states allow us to do that. We're also working with community organizations to make sure that first and foremost, that everyone who's eligible for coverage retains eligibility for coverage. I think that's probably where we start in this whole process, to ensure that those just because of administrative things, et cetera, have the right eligibility for the right program. For those that are not going to be eligible for Medicaid, again, we're working across our commercial business as well as our Medicaid business to provide, I think, the most education and seamless transition. If you think about our 14 commercial states, Medicaid membership in those states grew roughly 7.5 million beneficiaries in those states. We, as part of our exchange footprint, now cover pretty much all of the counties in our footprint of 14 states and also have incredibly strong market share, not only in the exchange, but also in our commercial benefits business. We think there's an opportunity, obviously, with our brand recognition, our dedication to this membership, our community involvement, and the work we're doing, again, with community partners, educating our commercial business, to be quite frankly well-positioned and don't see it as a jump ball. We think we're actually quite well-positioned in those states. In terms of our own, you know, Medicaid membership, approximately 2.7 million members, one million of those members came in as a result of the PHE. Obviously we know those members well. They know us well. They recognize our brand. Again, based on the state rules and regulations, we'll be working very closely to help that transition. I feel like, you know, given the time we've had to plan, the guidance from the administration, our work with the states, that actually this is going to be a much more organized process than I would call it just a jump ball, with a real opportunity for those who lead in the market, to have an opportunity to move those members and keep coverage, which again, is our primary goal here. Again, thanks for the question, and we look forward to continuing to update everyone on our progress there. Thank you. Next question. Next, we'll go to the line of Rob Cottrell from Cleveland Research. Please go ahead. Hi, good morning. Thanks for taking my question. I guess I just wanted to ask about, the negotiating environment with health systems. You know, there's been some conversation in the market about, financial pressures across health systems leading to increased value-based care adoption. Are you seeing that play out, across your negotiations and your contracting team? Do you expect that to ultimately, you know, have a positive impact for you all over the next year or two? Yes. Thanks for the question, Rob. A couple of things. One, you know, I think it's been well documented that, you know, our contracts are on a three-year in duration, so we negotiate again about a third of them each year. So that just gives you a little context to the sort of discussions. Clearly, you know, there is more cost pressure in the system, but overall, I would say our deals are coming in within normal range, and we continually are proactively managing that contract and our products, obviously, to offer affordability, continue to look at our clinical strategies, ensure we can maintain our long-term trends, while also, as we shared with you, maintain our underwriting discipline to price to our forward view of those costs. Now, ultimately, it's affordability that's paramount for our customers, particularly in this economic environment. We take that very, very seriously. Specifically to your question about value-based contracts with our providers, we are having those discussions, and quite frankly, we've made a lot of progress on our value-based contracts. We've shared with you roughly 60% of our total contracts are in value based, and our goal is to move a lot more of those, at least a third by 2025, to downside risk. I'm really pleased to share that we've made really good progress, even in this last year and in the last quarter and are now where we were in sort of low double digits now and high teens in downside risk. Making great progress against our goal to get some more downside risk in our contracts as well as value-based care. Back to your question, we do think that there is an opportunity to continue to move more of these to value-based care. We are seeing progress, not just on the hospital side, but across the broader provider care continuum. The other thing that I think is important, in trying to be a good partner with our care providers is we're also looking at how to reduce the administrative burden that they face. How do we accelerate the work we're doing on data sharing, reduce some of the, I'll call administrative care review processes that, you know, may not have the highest value. I think those are big opportunities for us as well, in addition to just trying to, increase rates. We've seen progress there, and we're committed to continuing to work with care providers so that, you know, obviously, that we have a good long-term partnership with them. Overall, we're not seeing anything outside of our normal ranges right now and have been very successful with these strategies. Thanks very much for the question. Next question, please. Next, we'll go to the line of Lisa Gill from JP Morgan. Please go ahead. Thanks very much for taking my question. Again, I want to go back to your earlier comment today around Sydney Health and virtual healthcare. You talked about, you know, 6 million visits per month. You talked about improving outcomes and costs. I'm really interested in when we think about 2023, are you offering a product in the marketplace where you have a lower premium where your primary care doctor is virtual? That would be my first question. Then secondly, is there a way to quantify when we think about the potential cost benefit of utilizing virtual primary care? Thanks for the question, Lisa. I'm going to ask Morgan to add some commentary, but just an overview. You know, Sydney is our front door to healthcare, so we have really embedded all of our capabilities in Sydney. And what I shared with you are a couple things. One, that virtual primary care is one of the elements of our care delivery strategy, and Morgan talk about the product offerings that we have there as well. But we're also seeing it, and you saw some of the early data around an opportunity to help us manage chronics in a much more efficient way. We're seeing a lot of uptake in that. And it's also embedded into what our customers are selecting, so we're adding a lot more capability inside of Sydney. A couple of very important just quick facts. Let me turn it over to Morgan to share with you a little bit about the product strategy, which is an element of our affordability offerings for the market. Right. Thanks, Gail, and thanks, Lisa, for the question. You know, when you think about the commercial group business, you've got, you know, generational cohorts, four of them with Boomers X, Y, and Z that are part of the actual the makeup. Of course, the way they engage certainly is indeed different. Various modalities are very important to us, and as such, we have products that we are launching, that have a virtual first component, where one can elect a primary care physician, that would be a digital connection as opposed to a physical connection. It also allows for the opportunity to move into the physical world within the value-based constructs that Gail described in our value-based network strategies, to keep a tight closed loop integration, so to speak, on how this works. One in particular that we've already launched for January first is in our Nevada market, which is a combination of a partnership with a single entity, but layered with a digital first front end. The economics of that arrangement are quite attractive in the market, and we're expecting nice pull through as the enrollment period concludes. You know, this is the beginning of it. We've been adding the virtual components to all of our commercial self-funded business and risk business over the past year and a half, and as such, we'll continue to build products anchored around those assets. Thanks again for the question. Yeah, thanks, Morgan. Lisa, just sort of two important concepts that I wanna reiterate. One, that we've embedded virtual capabilities for our customers across the board, and we're also aligning those with our high performance networks. When we talk about best cost in the marketplace and what's really driving a lot of our growth, it's that affordability. Again, it's not just virtual for virtual by itself, but it's aligned to our high performance network strategy. Then second, as Morgan said, we're in earlier days, but we have been beginning to launch a number of virtual only products. Again, they have tied to physical assets or high performance networks. Again, really trying to drive best cost and quality and outcomes for our members. Next question, please. Thank you. Next, we'll go to the line of Kevin Fischbeck from Bank of America. Please go ahead. Great, thanks. I guess I wanna go back to a comment that John made in prepared comments about the impact of a recession. I guess as a company historically has talked about, you know, the kind of balanced business mix between commercial Medicaid and how the two businesses kind of offset each other during a recession. Wanted to, I guess, first, you didn't mention a recession either as a tailwind, I'm sorry, as a headwind. I assume, does that mean that you don't assume a recession, the guidance, or you assume a modest one to have no impact? And then what exactly do you mean that if it's a severe recession, how should we think about how that impacts a company like Elevance given your business mix? Thanks. Yeah, thanks for the question, Kevin. I'll address that. I think that there's a few things. One, we are mindful of the economic environment under which, and John, in the headwinds and tailwinds, while we talked about, you know, one specific known Medicaid, he also did reference the broader economic environment that we're planning for across a whole series of scenarios. I wanna take you back in terms of our business because, you know, we are a much more diversified business than we have been at any other time in our company's history. Just putting some facts around that, you know, today that's 25% of our premium roughly is in our commercial business, whereas that number was 70% in 2008. As you think about that, you know, the diversity of our businesses. We've been able to perform in both good and bad economic times. Certainly, in stronger economic times, the commercial business continues to grow, but we haven't seen any impact in terms of our commercial business today, and we're still seeing strong growth in ASOs inside of our fee-based business. Clearly, our focus is on, as you just heard in the last question, affordable products driving a differentiated value for our consumers. We've been able to demonstrate that. Just a quick fact that we talk a lot about in our own business, our growth, as you've seen in the fee-based with some of our most discerning customers. We have been consolidating business from multi-carrier to single carrier over the last several years. We added another eight additional clients for January of this year that consolidate with us. These are just a couple of proof points in terms of the, I would say, the resiliency right now of our commercial business. And then obviously in more difficult times, Medicaid businesses tend to grow well and take on some of that. We're also in a very different environment than we were in the last recession. In that recession, we didn't have the ACA and the opportunity for individuals to go in in a subsidized manner. As you heard from us, we also now have full coverage in our counties in ACA exchange business. We think the Medicare business where we have zero premium plans is also quite resilient. You know, across our book, certainly we're mindful of an economic downturn. We're planning for it in our businesses. We've been investing heavily in digital and trying to ensure that we can maintain our own cost structure. Those are the kinds of things and playbooks that we have inside of our business. It's not that we're not planning and thinking about that business, but we do feel we have a much more resilient business and a much more diversified business that one business line isn't dominating our company as it had in the past. I would add that Carelon in times obviously adds. We have a big roadmap for Carelon to add additional opportunities to impact the affordability of our health plan business and take on more risk. Just a couple of the examples I shared this morning between AIM and myNEXUS. You know, we've got a I think a long runway there, and that again is all about driving affordability. I guess in short, yes, we're planning for it, yes, we're being prudent and diligent. We know that affordability and differentiated value is gonna be critical in a market where customers are strained, and those are the kind of products that we're putting in the market. We feel we've got a nice breadth of those right now, much more so than we've ever had. Thanks very much for the question. Next question, please. Next, we'll go to the line of Gary Taylor from Cowen. Please go ahead. Hi, good morning. I had a quick clarification for John and then maybe a quick one for Felicia. John, just on the reclass of the quality improvement incentives to G&A, just wondering if there's any rebate implications retroactively from that. For Felicia, as we look at the 2023 Medicare benefits offering, I mean, one of the key places where it really looks like Elevance stands out is in special supplemental benefits for chronically ill, just in your individual MA offering. Your funding level there really looks substantially higher than many of your competitors. I was just wondering why the focus on that benefit specifically and what% of your individual MA will avail themselves of that particular benefit? Thanks. Yeah. Thank you, Gary. I'll answer the first part of your question, then turn it over to Felicia for your second question. In terms of the impact on rebates, it was de minimis. You know, the vast majority of the reclassification impacted the commercial line of business. While we do have occasional MLR rebates in commercial, they're not nearly as prevalent as they are in Medicaid at this point in time. It was really de minimis. That's why I said there's virtually no bottom line impact. Felicia? Sure. Good morning, Gary. You know, when I think about our Medicare Advantage business, we've been always very focused on a portfolio that takes a look at individuals who are complex and chronic. Our dual special needs plans have always been an area where we look to grow. Today, I think we represent probably the third largest footprint with respect to dual-eligible individuals, and within our footprint, we're second. We believe that we have the capabilities as we sit within our Medicare business, and certainly as you take a look at Carelon, to be able to deliver a value proposition to these individuals that's differentiated. When we take a look at how we are appropriately priced and competitive in the marketplace, it's certainly based on our strategy around playing to those strengths and being able to partner and look to do those individuals or work with those individuals in a way that's differentiating. I think our competitive cost structure and the way that we think about our duals products certainly gives us the ability to address their specific needs. Thank you. Next question, please. Next, we'll go to the line of Whit Mayo from SVB Securities. Please go ahead. Hey, I just wanted to go back to Carelon for a second. Any way to frame what% of your post-acute spend for MA today is being delegated to myNEXUS or any of your other assets? Then, kind of what are the targets for that business over time? Just any way to quantify and put some numbers around it. I think, you know, I may have underappreciated the tail around this. Yeah. Thanks, Whit, for the question. You know, in terms of percentages, specific numbers on that, we're not gonna sort of get into that. The goal here is for our post-acute offering via myNEXUS to cover all of our Medicare Advantage business from a post-acute care perspective. We started on this journey in the middle of this year, launching in July. We've seen really good success. We also had another integration in September. We will complete all the Medicare Advantage markets in early 2023. You can assume more broadly that as it relates to post-acute care management for the Medicare business, we will be covering the management of all that population. Yeah. Thanks, Pete. A number that we do share more broadly is the percentage of spend that Carelon manages for Elevance Health, and that has continued to increase, and it's around 21%. Just to give you a little bit of perspective, and it's obviously a number that, you know, we continue to have a bigger impact on. Next question, please. Next, we'll go to the line of David Windley from Jefferies. Please go ahead. Hi. Thanks. I wanted to come back to the comments around commercial renewal. In John's prepared, you talked about being even more confident about January 1 than July 1, which was successful. Wondered if you could put a finer point on the factors that drive that confidence? Then to what extent do those same factors benefit growth beyond renewal and/or help your catcher's mitt for catching Medicaid from redetermination? Thank you. I'm gonna ask Morgan to address your question. Thanks, Dave. You know, to express confidence, I think the July played out as we indicated exactly as we expected. The renewals that we needed, we obtained, and of course, there was some attrition to book that was certainly planned. That same phenomenon we're seeing, and we're the very beginnings of it for January one. I think the confidence, That was alluded to earlier is in the actual position in which we're pricing the business. You know, we sort of got in the spot last year, pricing early for 2021 or 2022, and then things revealed differently in the fall. That's sort of shaping up as planned as we see right now. The confidence in the numbers in the market are there. When we think about this concept of a catcher's mitt with Medicaid redetermination, you know, there's business that stays on the Medicaid side, there's business that's going to move to the commercial side, be it group or individual. Gail alluded to the fact that we've done a really nice job in expanding our footprint to cover roughly 95% of the population of the geographies we serve commercial from a commercial individual ACA perspective. you know, we have very strong penetration in the commercial risk and non-risk business would also be part of that catcher's mitt, so to speak, for the group side. All in, we're confident in, A, the results from July, B, how we're lining up for January, and then lastly, that the catcher's mitt, based on proven performance and share, is gonna serve us well. Thank you for that question. Thank you, Morgan. We have time for one more question. Our final question comes from Stephen Baxter from Wells Fargo. Please go ahead. Yeah. Hi. Thanks for fitting me in. Just wanted to ask one follow-up on the group risk business. I was hoping you could give us a sense of what the in-group membership trends were in the quarter. Are you starting to see those slow a little bit as maybe the economy gets a little bit more uncertain? I guess basically what I'm trying to get a sense of is whether we can attribute all of the sequential decline to the attrition on the 7/1 renewals or whether the impact was larger or smaller than that and maybe masked by some of those in-group trends. Thank you. Yes. Thanks for the question. I think in total, I think I shared this in sort of the recession response. We really haven't seen a lot of change in-group, and actually it's been up a little bit. I wouldn't necessarily call it a trend, but it's been running fairly stable. I think as you think about, you know, where employers are, they're holding on to their employees. They've got a number of jobs still open. We're not seeing any impact yet across any of our commercial business on the attrition side, and actually are seeing some net adds. Thank you very much for the question, and thank you, operator. In closing, we're pleased with the broad-based momentum across our businesses and are confident that our ongoing execution of our strategy positions us to continue delivering against the financial targets we shared with you at our investor conference last year. We'll keep executing with excellence and discipline to deliver and enhance value to all of our stakeholders. Thank you for your interest in Elevance Health, and have a great rest of week. Ladies and gentlemen, a recording of this conference will be available for replay after 11 A.M. today through November 18, 2022. You may access the replay system at any time by dialing 800-813-5525, and international participants can dial 203-369-3346. This concludes our conference for today. Thank you for your participation and for using Verizon Conferencing. You may now disconnect.